FIELD: pharmaceutical industry.
SUBSTANCE: inventions group relates to the pharmaceutical industry, namely to the use of a composition containing a glucagon receptor antagonist (GCGR), which is an antibody or its antigen-binding fragment. The use of a composition containing a glucagon receptor antagonist (GCGR), which is an antibody or antigen-binding fragment, which contains: a heavy chain variable region (HCVR) containing HCDR1, HCDR2 and HCDR3 from HCVR, containing the amino acid sequence from SEQ ID NOs: 86; and a light chain variable region (LCVR) comprising LCDR1, LCDR2 and LCDR3 from LCVR comprising the amino acid sequence of SEQ ID NOs: 88 for lowering blood glucose and/or ketone bodies or treating a condition or disease associated or partially characterized by high blood glucose or elevated ketone bodies, or at least one symptom or complication associated with the condition or disease, in a patient with severe insulin resistance, comprising administering to a patient with severe insulin resistance a therapeutically effective amount of the composition such that blood glucose levels or ketone bodies are reduced, or the condition or disease is alleviated, or at least one symptom or complication associated with the condition or disease is alleviated or its severity is reduced; while a patient with severe insulin resistance: receives exogenous insulin in doses of more than 100-200 units per day, has chronically elevated levels of endogenous insulin in the blood, has fasting insulin levels above 50-70 mcU/ml, has peak insulin levels above 350 mcU/ml , has an insulin sensitivity index value below 2×104 mcU/mL⋅min, and/or demonstrates a glucose utilization rate below 2 mg/kg⋅min.
EFFECT: invention makes it possible to effectively alleviate the symptoms and conditions associated with severe insulin resistance.
48 cl, 4 dwg, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE THEREOF | 2018 |
|
RU2820628C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| ANTI-HUMAN ANGIOPOIETIN-LIKE 4 PROTEIN ANTIBODIES | 2010 |
|
RU2580045C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| BINDING DOMAINS OF ANTI-CD3 ANTIBODIES AND ANTIBODIES CONTAINING THEM, AS WELL AS METHODS OF THEIR PREPARATION AND APPLICATION | 2018 |
|
RU2807040C2 |
| ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND TREATMENT | 2020 |
|
RU2806915C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETED TO FC RECEPTOR-LIKE PROTEIN 5, AND THEIR USE | 2015 |
|
RU2779747C2 |
